Diego Díaz-García, CEO at CánCare, shared on X:
“In unresectable NSCLC, Stage III treated with CRT + durvalumab, ctDNA detection during and after durva was associated with a higher risk of progression:
- Before the 7th cycle: HR 2.45, p=0.013
- 3 months post-treatment: HR 5.37, p<0.001
- Multivariable model: HR 2.95, p<0.001
ctDNA detection after CRT, before durvalumab, was not prognostic. Serial ctDNA assessment could identify patients at high risk of relapse and candidates for alternative or intensification strategies, for now in the context of clinical trials.”
You might be interested in:
DeLLphi-305: Durvalumab + Tarlatamab Improves Survival in First-Line ES-SCLC
